Stock Track | Pharming Group Soars 20.11% on Stellar Q3 Results and Raised 2025 Guidance

Stock Track11-06

Pharming Group N.V. (NASDAQ: PHAR) shares surged 20.11% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical company reported significant growth in revenue and profitability, beating analyst expectations and raising its full-year guidance.

The company's total revenues for Q3 2025 increased by 30% year-over-year to $97.3 million, surpassing the analyst consensus estimate of $93.43 million. Pharming reported quarterly earnings of $0.10 per share, significantly beating the analyst estimate of breakeven results. This represents a substantial improvement from the $0.02 loss per share in the same period last year.

Key highlights from the report include a 29% increase in RUCONEST® revenues to $82.2 million and a 35% growth in Joenja® (leniolisib) revenues to $15.1 million. The company's operating profit surged by an impressive 285% to $15.8 million. Based on this strong performance, Pharming raised its full-year 2025 revenue guidance to $365-$375 million from the previous $335-$350 million range. The positive results were attributed to sustained growth in patients and prescribers for both RUCONEST® and Joenja®, as well as advancements in the company's product pipeline, including the FDA granting priority review for leniolisib in pediatric patients with APDS.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129475046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129475046","market":"nz","top_or_hot":-1,"title":"Stock Track | Pharming Group Soars 20.11% on Stellar Q3 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>Pharming Group N.V. (NASDAQ: PHAR) shares surged 20.11% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical company reported significant growth in revenue and profitability, beating analyst expectations and raising its full-year guidance.</p>\n\n<p>The company's total revenues for Q3 2025 increased by 30% year-over-year to $97.3 million, surpassing the analyst consensus estimate of $93.43 million. Pharming reported quarterly earnings of $0.10 per share, significantly beating the analyst estimate of breakeven results. This represents a substantial improvement from the $0.02 loss per share in the same period last year.</p>\n\n<p>Key highlights from the report include a 29% increase in RUCONEST® revenues to $82.2 million and a 35% growth in Joenja® (leniolisib) revenues to $15.1 million. The company's operating profit surged by an impressive 285% to $15.8 million. Based on this strong performance, Pharming raised its full-year 2025 revenue guidance to $365-$375 million from the previous $335-$350 million range. The positive results were attributed to sustained growth in patients and prescribers for both RUCONEST® and Joenja®, as well as advancements in the company's product pipeline, including the FDA granting priority review for leniolisib in pediatric patients with APDS.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pharming Group Soars 20.11% on Stellar Q3 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pharming Group Soars 20.11% on Stellar Q3 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharming Group N.V. (NASDAQ: PHAR) shares surged 20.11% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical company reported significant growth in revenue and profitability, beating analyst expectations and raising its full-year guidance.</p>\n\n<p>The company's total revenues for Q3 2025 increased by 30% year-over-year to $97.3 million, surpassing the analyst consensus estimate of $93.43 million. Pharming reported quarterly earnings of $0.10 per share, significantly beating the analyst estimate of breakeven results. This represents a substantial improvement from the $0.02 loss per share in the same period last year.</p>\n\n<p>Key highlights from the report include a 29% increase in RUCONEST® revenues to $82.2 million and a 35% growth in Joenja® (leniolisib) revenues to $15.1 million. The company's operating profit surged by an impressive 285% to $15.8 million. Based on this strong performance, Pharming raised its full-year 2025 revenue guidance to $365-$375 million from the previous $335-$350 million range. The positive results were attributed to sustained growth in patients and prescribers for both RUCONEST® and Joenja®, as well as advancements in the company's product pipeline, including the FDA granting priority review for leniolisib in pediatric patients with APDS.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAR","symbol_name":"Pharming Group N.V.","start_time":0,"source_url":"","article_id":"1129475046","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129475046","pubTimestamp":1762440077,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Pharming Group N.V. (NASDAQ: PHAR) shares surged 20.11% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHAR":"Pharming Group N.V."},"translate_title":"股票赛道|Pharming Group凭借出色的第三季度业绩飙升20.11%并上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAR":1},"content_text":"Pharming Group N.V. (NASDAQ: PHAR) shares surged 20.11% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical company reported significant growth in revenue and profitability, beating analyst expectations and raising its full-year guidance.\nThe company's total revenues for Q3 2025 increased by 30% year-over-year to $97.3 million, surpassing the analyst consensus estimate of $93.43 million. Pharming reported quarterly earnings of $0.10 per share, significantly beating the analyst estimate of breakeven results. This represents a substantial improvement from the $0.02 loss per share in the same period last year.\nKey highlights from the report include a 29% increase in RUCONEST® revenues to $82.2 million and a 35% growth in Joenja® (leniolisib) revenues to $15.1 million. The company's operating profit surged by an impressive 285% to $15.8 million. Based on this strong performance, Pharming raised its full-year 2025 revenue guidance to $365-$375 million from the previous $335-$350 million range. The positive results were attributed to sustained growth in patients and prescribers for both RUCONEST® and Joenja®, as well as advancements in the company's product pipeline, including the FDA granting priority review for leniolisib in pediatric patients with APDS.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129475046","isCrawlerRequest":true}